Kodiak Sciences (KOD)

Company Profile

Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.

Company profile

Ticker

KOD

Exchange

NASDAQ

Website

kodiak.com

CEO

Victor Perlroth

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis ...

Former names

Oligasis, LLC

SEC CIK

0001468748

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

270476525

KOD stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

EFFECT

Notice of effectiveness

5 Jun 23

EFFECT

Notice of effectiveness

15 May 23

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

15 May 23

Annual report to shareholders

25 Apr 23

DEFA14A

Additional proxy soliciting materials

25 Apr 23

Registration of securities for employees

28 Mar 23

Transcripts

KOD

Earnings call transcript

2020 Q1

13 May 20

KOD

Earnings call transcript

2019 Q3

13 Nov 19

Latest ownership filings

View all

VICTOR PERLROTH

14 Feb 23

SC 13G/A

PRICE T ROWE ASSOCIATES INC /MD/

Financial summary

Financial statements Chart KOD financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	322.94 mm	322.94 mm	322.94 mm	322.94 mm	322.94 mm	322.94 mm
Cash burn (monthly)	(no burn)	29.59 mm	24.87 mm	26.69 mm	15.74 mm	17.54 mm
Cash used (since last report)	n/a	66.37 mm	55.78 mm	59.85 mm	35.30 mm	39.35 mm
Cash remaining	n/a	256.57 mm	267.16 mm	263.09 mm	287.64 mm	283.59 mm
Runway (months of cash)	n/a	8.7	10.7	9.9	18.3	16.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

KOD institutional ownership history Ownership history

76.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	121	134	-9.7%
Opened positions	9	18	-50.0%
Closed positions	22	21	+4.8%
Increased positions	38	49	-22.4%
Reduced positions	48	38	+26.3%

13F shares	Current	Prev Q	Change
Total value	241.85 bn	292.45 bn	-17.3%
Total shares	40.01 mm	41.74 mm	-4.1%
Total puts	3.90 k	16.00 k	-75.6%
Total calls	18.60 k	170.00 k	-89.1%
Total put/call ratio	0.2	0.1	+122.8%

Largest owners	Shares	Value	Change
Baker Bros. Advisors	17.31 mm	$107.33 bn	0.0%
BLK Blackrock	4.42 mm	$27.38 bn	+3.0%
Vanguard	1.66 mm	$10.30 bn	+0.3%
D. E. Shaw & Co.	1.08 mm	$6.71 bn	-7.2%
ICONIQ Capital	1.02 mm	$6.30 bn	0.0%
STT State Street	990.98 k	$6.14 bn	+2.6%
Newtyn Management	892.74 k	$5.53 bn	+11.6%
Citadel Advisors	891.10 k	$5.52 bn	+187.6%
Acadian Asset Management	701.62 k	$4.35 mm	-4.0%
Board of Trustees of The Leland Stanford Junior University	691.77 k	$4.29 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Braidwell	0.00	-914.21 k	EXIT
Citadel Advisors	891.10 k	+581.31 k	+187.6%
Bruce & Co.	473.00 k	+473.00 k	NEW
T. Rowe Price	0.00	-472.01 k	EXIT
Millennium Management	0.00	-398.38 k	EXIT
FHI Federated Hermes	664.43 k	-263.84 k	-28.4%
MS Morgan Stanley	541.30 k	-219.80 k	-28.9%
Oasis Management	0.00	-168.91 k	EXIT
Voloridge Investment Management	0.00	-162.66 k	EXIT
Ikarian Capital	162.53 k	+162.53 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KOD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Dec 22	Victor Perlroth	Common Stock	Gift	Dispose G	No	No	0	60,000	0.00	3,448,038
6 Jul 22	Victor Perlroth	Stock Option Common Stock	Grant	Acquire A	No	No	8.15	325,000	2.65 mm	325,000
6 Jul 22	Borgeson John A.	Stock Option Common Stock	Grant	Acquire A	No	No	8.15	142,500	1.16 mm	142,500
6 Jul 22	Ehrlich Jason	Stock Option Common Stock	Grant	Acquire A	No	No	8.15	142,500	1.16 mm	142,500
30 Jun 22	Baker Bros. Advisors	NQSO Common Stock	Grant	Acquire A	Yes	No	7.64	25,000	191.00 k	25,000